Literature DB >> 9291

Cardiovascular response to exercise under increasing doses of chlorthalidone.

R I Ogilvie.   

Abstract

Five male subjects with essential hypertension received chlorthalidone at each of four dose levels (25, 50, 100, and 200 mg/day) for eight week periods each preceded by an eight week placebo period. Dosage order was randomized and double-blind. During the last week of each active and placebo period an upright bicycle exercise study was carried out at three loads (100, 200, 300 kpm/min) for 6 min each. Oxygen consumption at the maximal workload was 42% of predicted at a heart rate of 170. During placebo therapy, increasing workloads were associated with a progressive increase in blood pressure, heart rate, and pressure-rate index (systolic pressure times heart rate). With increasing doses of chlorthalidone up to 100 mg/day, there was a progressive reduction in blood pressure and pressure-rate index. At 200 mg/day there were paradoxical increases in diastolic pressures, heart rates and pressure-rate indices above values observed at 100 mg/day. With increasing doses of chlorthalidone, there was a progressive increase in arterial blood CO2 content and pH. Increasing workloads were associated with increased arterial blood lactate and decreased arterial blood lactate and decreased arterial blood pH. The changes in lactate and pH were not different at the different dose levels. The best antihypertensive effect in these exercising subjects was observed at a daily dose of 100 mg of chlorthalidone. The exercise response was useful in the determination of potentially adverse hemodynamic consequences of the larger dose of chlorthalidone.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 9291     DOI: 10.1007/BF00606546

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  The determination of gases in blood and other solutions by vacuum extraction and manometric measurement. I.

Authors:  D D Van Slyke; J M Neill
Journal:  J Biol Chem       Date:  2002-07-05       Impact factor: 5.157

2.  [Quantitative determination of L-(+)lactic acid with lactic dehydrogenase].

Authors:  F H BRUNS; H D HORN
Journal:  Biochim Biophys Acta       Date:  1956-08

3.  Studies of the pulmonary circulation at rest and during exercise in normal individuals and in patients with chronic pulmonary disease.

Authors:  R L RILEY; A HIMMELSTEIN
Journal:  Am J Physiol       Date:  1948-02-01

4.  Improved method for estimating chlorthalidone in body fluids.

Authors:  M G Tweeddale; R I Ogilvie
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

5.  Comparative exercise-cardiorespiratory performance of normal men in the third, fourth, and fifth decades of life.

Authors:  J S Hanson; B S Tabakin; A M Levy; D B Hill
Journal:  Circulation       Date:  1968-03       Impact factor: 29.690

6.  Effect of inspired O2 on cardiopulmonary and metabolic responses to exercise in man.

Authors:  R L Hughes; M Clode; R H Edwards; T J Goodwin; N L Jones
Journal:  J Appl Physiol       Date:  1968-03       Impact factor: 3.531

7.  Observations on the course of the metabolic events accompanying mild exercise.

Authors:  P Harris; M Bateman; T J Bayley; K W Donald; J Gloster; T Whitehead
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1968-01

8.  Renin, norepinephrine, and epinephrine responses to graded exercise.

Authors:  T A Kotchen; L H Hartley; T W Rice; E H Mougey; L G Jones; J W Mason
Journal:  J Appl Physiol       Date:  1971-08       Impact factor: 3.531

9.  Cardiovascular responses to submaximum and maximum effort cycling and running.

Authors:  J A Faulkner; D E Roberts; R L Elk; J Conway
Journal:  J Appl Physiol       Date:  1971-04       Impact factor: 3.531

10.  Hemodynamic and oxygen transport responses to exercise in hypertensive and normotensive age peers: effects of hypotensive drug treatments.

Authors:  W P Johnson; J W Jones
Journal:  Am J Med Sci       Date:  1967-02       Impact factor: 2.378

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.